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Almost 50 million people in the world are affected by dementia; the most prevalent
form of which is Alzheimer’s disease (AD). Although aging is considered to be the main
risk factor for AD, growing evidence from epidemiological studies suggests that type 2
diabetes mellitus (T2DM) increases the risk of dementia including AD. Defective brain
insulin signaling has been suggested as an early event in AD and other tauopathies but
the mechanisms that link these diseases are largely unknown. Tau hyperphosphorylation
is a hallmark of neurofibrillary pathology and insulin resistance increases the number of
neuritic plaques particularly in AD. Utilizing a combination of our Drosophila models of
tauopathy (expressing the 2N4R-Tau) and neuroblastoma cells, we have attempted to
decipher the pathways downstream of the insulin signaling cascade that lead to tau
hyperphosphorylation, aggregation and autophagic defects. Using cell-based, genetic,
and biochemical approaches we have demonstrated that tau phosphorylation at AT8
and PHF1 residues is enhanced in an insulin-resistant environment. We also show that
insulin-induced changes in total and phospho-tau are mediated by the crosstalk of AKT,
glycogen synthase kinase-3β, and extracellular regulating kinase located downstream of
the insulin receptor pathway. Finally, we demonstrate a significant change in the levels
of the key proteins in the mammalian target of rapamycin/autophagy pathway, implying
an increased impairment of aggregated protein clearance in our transgenic Drosophila
models and cultured neuroblastoma cells.
Keywords: Alzheimer’s disease, type 2 diabetes, tau aggregation, autophagy, tau hyper-phosphorylation
Abbreviations: 4EIBP, eukaryotic initiation factor 4B; AD, Alzheimer’s disease; ERK, extracellular regulating kinase; GMR,
glass multimer reporter; GOF, gain of function; GSK, glycogen synthase kinase; HD, Huntington’s disease; IRS, insulin
receptor substrate; LOF, loss of function; mTOR, mammalian target of rapamycin; NFT, neurofibrillary tangle; p70S6K,
p70S6kinase; PD, Parkinson’s disease; T2DM, type 2 diabetes mellitus; UAS, GAL4-responsive upstream activating sequence;
wt, wild type.
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INTRODUCTION
Alzheimer’s disease is a widely prevalent form of dementia
that is characterized by loss of memory and other cognitive
functions required to perform complex daily activities (Citron,
2004). Aging remains the most important risk factor for AD,
but population-based studies have identified T2DM, an age-
associated chronic metabolic disorder, as a major risk factor
for developing cognitive impairment and dementia (Barbagallo
and Dominguez, 2014; Sridhar et al., 2015). Insulin resistance in
peripheral tissues is a key feature of T2DM, and accumulating
evidence suggests that insulin resistance also develops in AD
and other tauopathies in early stages of the disease (Goncalves
et al., 2019). Recent studies have also shown that brain insulin
resistance can develop independently from systemic insulin
resistance. However, the underlying mechanisms that lead to
persistent brain insulin resistance and needs to be investigated
(Triani et al., 2018). Several studies have demonstrated that
both insulin and insulin receptors (IRs) are found in the brain,
and IR are highly expressed in neurons of the central nervous
system (CNS) (Talbot et al., 2012; O’Neill, 2013). FDG-PET
studies in AD patients have shown a progressive impairment
of cerebral glucose uptake and metabolism particularly in
the parieto-temporal lobes and posterior cingulate cortical
regions of the brain that correlates strongly with disease
progression (Moloney et al., 2010). Moreover, insulin and
insulin-sensitizing drugs improve cognitive performance in
people at early stages of AD (Freiherr et al., 2013; Roberts
et al., 2014). The physiological and pathological role of IR
signaling in the CNS is still unknown, but a strong correlation
between AD and dysfunction of the insulin-signaling pathway
with regard to glucose metabolism in the brain has prompted
some investigators to refer to AD as type 3 diabetes or an
“insulin resistant” condition of the brain (de la Monte, 2012;
Barone et al., 2019).
Pathophysiologically, NFTs composed of aggregated and
hyperphosphorylated tau are a hallmark of AD and other
tauopathies (Augustinack et al., 2002; Steen et al., 2005).
GSK-3β is a key serine/threonine kinase that phosphorylates
tau at pathological epitopes at proline directed serine and
threonine residues (Jackson et al., 2002; Johnson and
Bailey, 2002). Additionally, GSK-3β inactivates glycogen
synthesis and forms an important component of the
insulin signaling pathway (Doble and Woodgett, 2003;
Jolivalt et al., 2008). Another non-proline directed kinase
that acts downstream of the insulin signaling pathway
and generates pathological phospho-tau epitopes under
conditions of oxidative stress is ERK (Colucci-D’Amato
et al., 2003; Diehl et al., 2017). Although evidence of tau
hyperphosphorylation by GSK-3β and ERK strongly indicates
an impairment of the IR pathway as a risk factor in AD, the
underlying mechanisms that link insulin resistance to tau
hyperphosphorylation remain unclear.
The disease and severity of AD correlates strongly with the
spatial and temporal progression of the insoluble aggregated
tau fragments (NFTs) in the vulnerable brain regions (Didonna
and Legname, 2010). Recent studies have shown that the
clearance of these misfolded tau aggregates from the neurons
is accomplished by autophagy (Smith, 2002; Lee, 2012). Thus,
a prominent feature of AD is the massive accumulation
of lysosomal vesicular structures in degenerating neurons,
and pathological studies have suggested an impairment of
macroautophagy in neurodegenerative disorders including AD
and other tauopathies (Codogno and Meijer, 2010; Barnett
and Brewer, 2011; Nassif and Hetz, 2012). Macroautophagy
involves the formation of double membrane bound structures
around cytosolic protein aggregates and forming autophagic
vacuoles, which will subsequently fuse with the lysosomes for
the degradation of protein aggregates and cellular organelles. The
mTOR plays an important role in cellular homeostasis and is
an inhibitor of autophagy (Jung et al., 2010). There are reports
from a large body of literature, that insulin signaling leads to
the activation of AKT and mTOR via a relay of phosphorylation
events (Partridge et al., 2011). Phosphorylation of mTOR via
the PI3K-AKT signaling pathway induces protein synthesis
and downregulates autophagy, whereas dephosphorylation of
mTOR has the opposite effect (Avet-Rochex et al., 2012). Several
groups have shown that the PI3K/AKT/mTOR pathways are
activated in the early stages of AD, while other groups have
shown an upregulation of autophagy in the AD brains (Cai
et al., 2012; O’Neill, 2013). However, the exact mechanism
of autophagic induction and misfolded protein clearance in
neurodegeneration especially with regard to insulin resistance,
still remains uncertain.
Drosophila models misexpressing the full-length human
tau have been used successfully by us and many others
to recapitulate prominent features of human tauopathies
that include progressive neurodegeneration and tau
aggregation/phosphorylation at the disease-associated
phospho-epitopes mediated by the key kinases (Jackson
et al., 2002; Chatterjee et al., 2009). Likewise, human
neuroblastoma cells (SHSY5Y) have been used as in vitro
models for the study of AD and other neurodegenerative
diseases (Tanaka et al., 1995; Lesort et al., 1999;
Jamsa et al., 2004).
We have previously demonstrated that the misexpression
of full-length (2N4R) human tau under the control of a
glass promoter in the fly retina causes a marked “rough
eye” phenotype with reduced eye size and missing bristles
(Chatterjee et al., 2009). This “rough eye” phenotype has been
instrumental in performing genetic screens to identify the
modifiers of tau toxicity. Interestingly, an unbiased genetic
screen conducted with the gl-Tau flies identified “Chico” –
the single fly homolog of the mammalian IRS as one of
the suppressors of the tau-induced “rough eye” phenotype
(Ambegaokar and Jackson, 2011).
We therefore investigated the effect of insulin on tau
phosphorylation in vivo by co-expressing Chico with Tau
in the Drosophila retina. Our findings demonstrate that
Chico has a strong genetic interaction with Tau, causing
a suppression of tau-induced toxicity in our model. We
also observe that Chico decreases the level of total tau
(T46) as well as phosphorylated tau at AT8 (phospho-
Ser202/Thr205) and PHF1 (phospho-Thr231/Ser235) sites.
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This effect correlates strongly with an elevation of inactive
p-GSK-3βS9, while decreasing the level of active p-ERK
(p-p44/42). We further demonstrate that these traits are
reversed by Chico loss-of-function (Chico-LOF) indicating
a Chico-specific effect on tau pathology. Finally, we show
an increased proportion of soluble and insoluble tau
aggregates in Tau transgenics that is accompanied by an
induction of autophagy though not necessarily autophagic
clearance. Interestingly, these effects are rescued by Chico
but aggravated by Chico-LOF. We further validated our
findings in vitro in human neuroblastoma cells under
insulin resistant conditions. Collectively, these results
show that the mechanisms by which insulin resistance
impacts tau pathology are conserved in Drosophila and
mammalian cell lines.
MATERIALS AND METHODS
Stocks and Genetics
Flies were grown on Jazz mix medium (Applied Scientific Jazz
Mix, Fisher Scientific, Pittsburgh, PA, United States) at 25◦C.
The GAL4 driver used in this study is GMR-GAL4 on the X
chromosome. GMR-GAL4 (X) was placed in trans to gl-tau (A
direct fusion construct of the human full-length tau cDNA to
the eye specific glass promoter as described by (Jackson et al.,
2002) to generate GMR-GAL4-gltau on the X chromosome.
Transgenic fly lines carrying UASChico were established by
amplifying target sequences by PCR using chico specific primers
(chico forward: 5′-ATAATTCCGCACTGGCAAAG-3′; chico
reverse: 5′-CCATGCCATTAAGATGCTCA-3′) and the resulting
constructs were subcloned using Exelixis (San Francisco, CA,
United States) modification of Drosophila upstream activation
sequence (UAS) expression vector (pEx-UAS) and microinjected
into fly embryos (BestGene, Chino Hills, CA, United States).
UASChico-RNAi and Chico-LOF flies were a gift from Dr.
Minoru Saitoe (Tokyo Metropolitan Institute of Medical
Science). UASEGFP was ordered from Bloomington Fly Stock,
Indiana, Stock no. 5431). The EGFP gene is located on the
second chromosome.
Light Microscopy
Light microscopy retinal images were acquired using a Nikon
AZ100M light microscope (Melville, NY, United States).
Extended depth of focus and volumetric images were taken
using a Nikon DSFi1 camera and Nikon NIS-Elements AR
3.0 software as described previously (Chatterjee et al., 2009;
Ambegaokar and Jackson, 2011).
Histology and Immunohistochemistry
For SEM, flies were dehydrated in ethanol, incubated overnight
in hexamethyldisilazane, dried under vacuum, attached to
stubs with black nail polish and analyzed using a JSM-
6510LV SEM (JEOL USA, Peabody, MA, United States)
(Chatterjee et al., 2009). TRITC phalloidin (Sigma, St. Louis,
MO, United States) whole-mount staining of adult retina
was carried out as described previously (Sang and Ready,
2002). Briefly, adult retinas were dissected in cold PBS 1X
pH 7.4, fixed in 4% formaldehyde/PBS for 45 min, then
washed three times in PBT (0.5% Triton in PBS) and
incubated for 40 min with TRITC-Phalloidin. After three washes
in PBT, samples were mounted in vectashield for analysis
with SP8 AOBS Laser Scanning Confocal Microscope (Leica
Microsystems, Germany). 63× objective was used for scanning
the retinas using a 561 nm laser spectral detector of detection
bandwidth 550–650 nm.
Immunoblotting and Reagents in
Drosophila
Immunoblotting experiments were performed according
to protocols previously described (Chatterjee et al., 2009).
Briefly, about thirty freshly eclosed flies were collected and
heads were decapitated and homogenized using an Argos
battery-operated pestle mortar mixer for 1 min on ice in lysis
buffer supplemented with complete protease inhibitors and
PhosphoSTOP phosphatase inhibitor (Roche Diagnostics,
Indianapolis, IN, United States). Extracts were then centrifuged
at 4◦C for 10 min at 11,000 × g and the supernatants were
collected while the pellets were discarded. Samples were
then mixed with an equal volume of Laemmle sample
buffer with β-mercaptomethanol (Bio-Rad Laboratories,
Hercules, CA, United States) and resolved by appropriate
SDS-PAGE gels before transfer to nitrocellulose membranes
for antibody labeling. The membranes were then incubated
with appropriate secondary antibodies and developed using
enchanced chemiluminiscence (ECL). Following western
blot detection the membranes were re-probed with anti-
β-tubulin or anti-β-actin that was used as a loading control
for each experiment. The following antibodies were used,
anti-tau monoclonal antibody (1:1000; T46, Invitrogen),
AT8 (1:500; Thermo Scientific), anti-P-AKT505, anti-AKT,
anti-mTOR, anti-P-p70S6K, and anti-P-4E-BP (1:500; Cell
Signaling), anti-P-GSK-3βS9 (1:500; Genetex), GSK-3β (1:1000;
United States Biologicals), anti-P-p44mapk, and p44mapK
(1:500; Promega), anti-Re f(2P) (1:500; Abcam), anti-ATG8
(1:400; EMD Millipore), anti-β-tubulin, and anti-β-actin
(1:2000; Sigma). The blots were quantified by ImageJ (NIH).
Western blots were repeated at least three times with different
sets of animals.
Cell Culture and Treatments
SY5Y human neuroblastoma cells were ordered from ATCC
and grown in DMEM supplemented with 10% heat-inactivated
fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 µg/ml streptomycin in 5% CO2 atmosphere at 37◦C. Cells
were plated at a density of 5 × 103 cells/cm2 in 60 mm-diameter
culture dishes with 10% FBS. From day 1 after plating, cells were
differentiated in the presence of 10 µm all-trans retinoic acid for
a week in the cell medium containing 1% FBS. For experiments,
4 × 106 cells were seeded on 60 mm dishes and cultured for
48 h (Jamsa et al., 2004). Briefly, the cells were serum-starved
for 24 h and then incubated in the absence and presence of
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insulin (100 nm) for time periods of 10 min, 30 min, 1, 2, and
4 h, respectively.
In parallel, the cells were serum starved for 24 h and
then incubated with 100 nm insulin for a period of 48 h.
Post-incubation the medium was removed and supplemented
progressively with 20 nm insulin for a period of 4 h, respectively.
For the study of autophagic flux the cells were incubated with
100 nm bafilomycin for 4 h prior to processing. DMEM, fetal
bovine serum, L-glutamine, penicillin, streptomycin, and other
cell culture reagents were obtained from Life Technologies, Inc.
(Invitrogen), Recombinant human insulin and trans–retinoic
acid was from Sigma.
Immunoblotting in SY5Y Cells and
Reagents
Following insulin treatment, cells were lysed in buffer containing
50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1% Triton-X-100,
1 mM EDTA, 10 mM NaF, 1 mM Na3VO4, and one complete
protease inhibitor cocktail tablet (Roche Diagnostics)/10 ml
buffer. Cell lysates were centrifuged at 15,000 × g (Eppendorf
5417R) for 10 min. The protein content of the supernatants
was measured using BCA Protein Assay kit (Pierce). An
equal amount of total protein was resolved on 4–20% SDS-
polyacrylamide gel electrophoresis for immunoblotting
analysis using standard protocols. Primary antibodies were
incubated overnight at 4◦C at the following dilutions,
T46 (1:1000; Invitrogen), AT8 (1:500; Thermo Scientific),
pGSK-3βS9, pAKT473, mTOR, P-p70S6K, P-4E-BP1, GSK-
3β, AKT, anti-IRS1-pSer616 (1:500; Cell Signaling), pERK,
ERK (1:500; Promega), anti-LC3 (1:400; Novus Biologicals),
and anti-GAPDH (1:500, Abcam), anti-β-actin (1:5000;
Sigma). Horseradish peroxidase (HRP) conjugated secondary
antibodies (Amersham Biosciences) were incubated for 1 h
at room temperature in 5% milk at the dilution of 1:2000
for anti-mouse and anti-rabbit antibodies. The blots were
developed by ECL.
Immunocytochemistry and Reagents
Serum-starved SY5Y cells were stimulated at different time
points with or without insulin (100 nm). After a brief PBS
wash, cells were fixed for 30 min in 4% paraformaldehyde-
PBS, washed three times in PBS, and blocked in 3% BSA
for 1 h. Cells were then incubated with total tau antibody
(A0024, DAKO) and p62 (NBL) at 1:200 dilution overnight at
4◦C. After extensive washing with PBS, cells were incubated
with Alexa Fluor 568 nm conjugated goat anti-mouse IgG
(Invitrogen) and Alexa Fluor 488 nm conjugated goat anti-
rabbit IgG (Invitrogen) and counterstained with 4, 6-diamino-
2-phenylindole (1:3000 dilution) to count the number of
nuclei per field of view. Cells were mounted in coverslips
with vectashield (Vector laboratories). Cell analysis was carried
out using a Zeiss Axioplan 2 MOT upright fluorescence
microscope equipped with filter sets for DAPI, FITC, and TRITC.
The microscope settings were consistent for experimental
and control sets.
Statistical Analyses
Comparison between multiple groups in flies was done by
one way ANOVA followed by Tukey-Kramer HSD test.
Two experimental groups were analyzed using Student’s
t test. Comparison between multiple groups in SY5Y
cells were carried out by one way ANOVA followed
by Fisher’s LSD post hoc test. Comparison between
two experimental groups was done by Student’s t test.
Statistical analyses were performed using Graphpad Prism
or Sigma Plot software.
RESULTS
Several groups have shown that Chico plays a prominent
role in the insulin-signaling pathway in Drosophila with
Chico-LOF generating pronounced insulin resistance (Murillo-
Maldonado et al., 2011; Naganos et al., 2012). Our previous
studies from an unbiased genetic screen in Drosophila
tauopathy models, have identified Chico as a strong modifier
of the Tau phenotype. Hence, in the next sections we have
investigated further the mechanistic pathways by which this
interaction occurs.
Misexpression of Chico in the Fly Eye
Ameliorates Human Tau Induced
Rough-Eye Phenotype
To investigate how insulin signaling impacts tau pathology, we
utilized our well-established model of Tauopathy in which we
expressed full-length wild type human Tau (2N4R) in Drosophila
eyes using the pan-retinal GMR-GAL4 driver (Jackson et al.,
2002; Chatterjee et al., 2009). As reported previously, Tau
misexpression in the eye resulted in smaller eye size with a
rough anterior and missing bristles (Figure 1C). Interestingly,
co-expression of Chico with Tau ameliorated the “roughness”
of the eye phenotype, resulting in larger eyes with fewer
missing bristles (Figure 1D) while ChicoRNAi or Chico-LOF
(null allele chico[1]) with Tau, resulted in a more severe
worsening of the “rough-eye” phenotype (Figures 1F,G). As
compared to the double transgenics, the Control eyes of
(GMR/+), GMR/UASChico and GMR/UASChicoRNAi appeared
perfectly normal (Figures 1A,B,E). Magnification of the SEM
insets (400X) clearly demonstrates fused ommatidia and
missing bristles in Tau flies (Figure 1C, lower panel) that
are partially rescued by Chico (Figure 1D, lower panel)
and exacerbated by Chico-LOF (Figure 1F, lower panel).
Quantification of the percentage of rough area per eye in
each genotype revealed an 80% rough-eye area in Tau and
Tau+Chico-LOF dual transgenics as compared to 45% rough-
eye area in Tau+Chico transgenics compared to Controls
(Figure 1H, lower panel). In contrast, UASEGFP co-expressed
with Tau, failed to suppress the “rough-eye” phenotype
confirming that the effect of Chico on Tau is specific
(Supplementary Figure S1A).
In order to compare the internal retinal morphology,
confocal imaging of adult retinas stained with TRITC-phalloidin
was performed. Tangential optical sections display a normal
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FIGURE 1 | Overexpression of Tau induces a rough eye phenotype that is partially suppressed by Chico coexpression; conversely Tau coexpressed with Chico-RNAi
or Chico-LOF restores the rough eye phenotype. (A–G) Displayed are photomicrographs and scanning electron microscopy of progeny eyes taken 24–48 h
post-eclosion; (A) driver alone, (B) Chico, (C) Tau, (D) Tau+Chico, (E) Chico-RNAi, (F) Tau+Chico-RNAi, (G) Tau+Chico-LOF (null allele). Scale bars, 50 µm for the
light micrographs and 200 µm for the scanning electron micrographs. (H) Quantitation of the percentage of “Rough eye” phenotypes in Tau, Tau+Chico, and
Tau+ChicoRNAi transgenics. Error bars represent SEM. N = 15 eyes/genotype, ∗∗∗P < 0.001 relative to Tau flies. Student’s t test was done for pairwise comparison
between two groups.
trapezoidal array of rhabdomeres in the driver-alone controls
(Supplementary Figure S2A). In contrast, Tau flies produced
disorganized ommatidia with massive loss of photoreceptor
neurons (Supplementary Figure S2B). The retinas of transgenics
co-expressing Chico (Supplementary Figure S2C) showed
a relatively normal array of rhabdomeres other than some
abnormal polarity.
Taken together our results show that the co-expression of
Chico with Tau atleast partially rescues tau-induced neuronal loss
and protects against tau-induced neurotoxicity.
Misexpression of Chico With Tau
Reduces the Levels of Total and
Hyperphosphorylated Tau
We and others have previously shown that the “roughness” of
the eye phenotype in Tau transgenics is associated with elevated
tau expression as well as hyperphosphorylation at the disease
epitopes (Jackson et al., 2002; Chatterjee et al., 2009). Therefore,
in order to analyze the rescue of the “rough-eye” phenotype in
Tau+Chico flies, we examined if there were any alterations in the
levels of total and hyperphosphorylated tau in these transgenics.
Our results show that coexpression of Chico and Tau
significantly decreased the total tau (T46) and phospho-tau
at AT8 and PHF1 residues leading to >50% reduction of
AT8/T46 and PHF1/T46 ratios as compared to Tau-alone flies.
We further observed that these effects were reversed when Tau
was coexpressed with Chico-LOF or ChicoRNAi (Figure 2A and
Supplementary Figure S3A). Our data also showed that the
coexpression of EGFP produced no alterations in the tau levels
confirming that this is a Chico-specific effect (Supplementary
Figure S1B). In summary, our results suggests that the ability
of Chico to ameliorate the tau-induced “rough-eye” phenotype
occurs by decreasing the level of total and phospho-tau at
pathological epitopes.
Misexpression of Chico With Tau
Decreases the Formation of Soluble and
Insoluble Tau Aggregates Compared to
Tau and Tau+ChicoRNAi
Aggregation of hyperphosphorylated tau is one of the key
features of AD and related tauopathies (Simic et al., 2016).
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FIGURE 2 | Western blot data shows a decrease in the levels of total (T46) and phosphorylated tau (AT8, PHF1) when Chico is coexpressed with Tau; the T46 and
AT8 levels are reversed when Chico-RNAi is coexpressed with Tau. (A) Representative blots are probed with T46 (total tau), AT8, PHF1, (phospho-tau), and β-tubulin
antibodies, respectively. All flies were 3 days after eclosion. Genotypes are as follows: GMR-GAL4/+; GMR-GAL4/UASChico; GMR-GAL4-gl-Tau/+;
GMR-GAL4-gl-Tau/UASChico; GMR-GAL4/UASChico-RNAi; GMR-GAL4-gl-Tau/UASChico-RNAi. (B) Tau and Chico coexpression decreases the level of sarcosyl
soluble and insoluble tau aggregates in the supernatant and pellet as compared to Tau alone and Tau+Chico-LOF dual transgenics. Western blot analysis from flies
probed with T46 antibody against total tau. Genotypes: GMR-GAL4-gl-Tau/+; GMR-GAL4-gl-Tau/UASChico; GMR-GAL4-gl-Tau/UASChico-LOF. Densitometric
analyses of AT8/T46 and PHF1/T46 levels and total tau distribution in soluble and pellet fractions are normalized to β-tubulin. (One way ANOVA with Tukey-Kramer
HSD was used for multiple groups comparison or post hoc Dunnett’s test for comparison against Tau, n = 3 sets of biological replicates for each genotype.) Data
represents the mean ± SEM, ∗∗P < 0.01 and ∗P < 0.05 relative to Tau.
Our previous studies in tauopathy models demonstrated the
accumulation of sarcosyl soluble and –insoluble tau aggregates
that contributed toward tau-induced neurotoxicity (Chatterjee
et al., 2009). In line with these reports, we investigated
whether loss or GOF of Chico has any effect on sarcosyl
solubility of tau. Co-expression of Chico with Tau reduced
the accumulation of sarcosyl-soluble and insoluble tau species
in the supernatant and pellet fractions, respectively. However,
co-expression of ChicoRNAi significantly altered the pattern
of tau solubility and increased accumulation of sarcosyl-
insoluble tau (Figure 2B). Although recent studies have
demonstrated that soluble tau aggregates are toxic for neuronal
cells, sarcosyl-insoluble tau aggregates eventually form the
NFTs detected in AD brains (Ren and Sahara, 2013). Taken
together, our data shows that in addition to decreasing
tau expression and hyperphosphorylation, Chico reduces the
formation of sarcosyl-soluble and insoluble tau aggregates in
Tau transgenics.
Effect of Chico on Tau
Hyperphosphorylation Is Mediated by
GSK-3β
Given that the insulin signaling pathway in Drosophila is highly
conserved with that of higher vertebrates, and the kinases GSK-
3β and ERK lie downstream of Chico in the insulin signaling
cascade; we investigated whether there is a direct effect of Chico
on the regulation of these kinases in our model.
Our data showed a >50% reduction in the level of inactive
p-GSK-3βS9 in Tau genotypes compared to controls (GMR/+
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and GMR/UASChico) that matched with the elevated tau
phosphorylation at AT8 and PHF1 epitopes. Co-expression
of Chico with Tau rescued the levels of phospho-GSK-3βS9
while Tau+ChicoRNAi lines reversed the effect (Figure 3A).
Conversely, when active GSK-3β (phospho-GSK-3βY216)
levels were assessed; Tau+Chico transgenics showed a
marked reduction in active GSK-3β compared to Tau-only
and Tau+ChicoRNAi transgenics (data not shown).
Next, we analyzed the phosphorylation status of active ERK
(p42/44) and observed <10% reduction in Tau transgenics
compared to Controls. Interestingly, this effect was not rescued
by either Chico overexpressed or knock-down lines (Figure 3A).
Despite the alterations in phosphorylated GSK-3β and ERK, total
protein levels remained constant in all the genotypes.
Collectively, our data suggests that Chico-mediated effects of
tau hyperphosphorylation display a direct correlation with GSK-
3β but not with ERK.
To assess whether insulin resistance was generated by the
gain or LOF of Chico, we analyzed the ability of Chico to
stimulate AKT phosphorylation at position Serine505. This
phospho-AKT site in flies is analogous to mammalian AKT
phosphorylated at Serine473 and a marker of insulin sensitivity
(Musselman et al., 2011). We observe that compared with other
genotypes, the Tau+ChicoRNAi lines show a 50% reduction
in phospho-AKTSerine505 levels suggesting an insulin-resistant
phenotype (Figure 3B).
Tau-Induced Down-Regulation of TOR
Pathway Components Is Rescued in
Tau+Chico Double Transgenics
As in higher vertebrates, in Drosophila, the insulin signaling
pathway is upstream of IRS/PI3K pathway, which in turn
positively regulates target of rapamycin (TOR) activity. In
a healthy environment, TOR activates protein synthesis and
promotes cellular growth and proliferation by enhancement of
important translational components, including the translation
initiation factor 4E binding proteins (4E-BP1-3) and ribosomal
protein S6 kinases. However, under stressful conditions, TOR
signaling is impaired and autophagy is upregulated (Cai et al.,
2012; O’Neill, 2013). Interestingly in our studies, we observed
a 40% reduction of the TOR pathway components phospho-
p70S6K and phospho-4E-BP1 in the Tau flies with a partial rescue
observed in Tau+Chico transgenics (Figure 4A). In addition, we
assessed the TOR protein levels in the Tau flies. A significant
reduction of phospho-TOR/Total TOR was found in Tau flies
compared to Control and Chico-only flies. This effect was rescued
partially by Chico co-expression (Supplementary Figure S4A).
Upregulation of Autophagy Is Observed
in Tau and Tau+ChicoRNAi Transgenics
Previous studies have demonstrated that the inactivation of the
TOR pathway stimulates basal autophagy (Hands et al., 2009;
Metcalf et al., 2012; O’Neill, 2013). The Drosophila homologs of
mammalian autophagy marker LC3 are Atg8a and Atg8b. Atg8a
particular, has been extensively used as an autophagy marker in
Drosophila. The lipidation of Atg8a produces Atg8a-II that is
directed to the autophagosomes as opposed to Atg8a-I, which is
the unprocessed Atg8a protein (Nagy et al., 2015). Compared to
other genotypes Tau transgenics showed significant upregulation
of autophagy that was partially reduced by Chico. Interestingly,
Tau+Chico-LOF flies displayed a similar enhancement of
autophagy (Figure 4B and Supplementary Figure S5).
However, an increase in Atg8a-II signal implies an enhanced
autophagic induction but not necessarily an autophagic clearance
(Rusten and Stenmark, 2010). Hence we decided to investigate
if there was an alteration in the levels of Ref(2P) – the fly
homolog of mammalian p62 which accumulates due to an
impairment in autophagy (Son et al., 2012). Although there
was a moderate increase of Ref(2P) accumulation in Tau and
Tau+Chico-LOF, it was not significant compared to other
genotypes (data not shown). Thus, in summary, our data
suggests that Tau overexpression induces autophagy without an
autophagic blockage.
Progressive Insulin Treatment of SY5Y
Cells Causes a Time-Dependent
Increase in Total and Phosphorylated Tau
That Correlates With the Decrease of
Inactive GSK-3β
To determine whether the insulin-induced alteration in the
total and phospho-tau levels that we observe in our Drosophila
tauopathy models, is conserved in human cells, we next
investigated the effect of insulin treatment in neuroblastoma
cells. SY5Y cells were serum-starved for a period of 24 h and
then treated with 100 nm insulin for 8 h (Son et al., 2012).
We observed an immediate decrease in T46 (total Tau) and
AT8 (Serine 202/Threonine 205) that lasted for a period of
30 min of insulin treatment, followed by a gradual increase
in the levels of total and AT8-tau over a period of 4 h after
which it remained constant. However, as the insulin treatment
continued for a period of 4 h, AT8-tau levels were significantly
elevated as compared to total tau (T46), thereby increasing
the ratio of AT8/T46 by almost 2.5-fold (>50%) at 4 h as
compared to controls (0 min post-treatment) (Figure 5A and
Supplementary Figure S3B).
Next, we examined the change in phospho-IRS-1(Ser636) at
specified time intervals to monitor insulin resistance in the cells.
From 30 min to 4 h we observed a gradual increase in the ratio
of phospho-IRS1(Ser636)/Total IRS1 levels consistent with an
insulin-resistant phase in our cellular model (Figure 5B).
Insulin resistance in animal and cellular models of type 2
diabetes is also marked by a reduction in phospho-AKTSer473
while total AKT remains constant (Shao et al., 2000; Standaert
et al., 2002). Our data showed that phospho-AKTS473 levels
did not change significantly compared to control till a period
of 30 min. However, post-insulin treatment there was a gradual
decrease of phospho-AKT/Total AKT signal from 1 h (50%
reduction) to 4 h (80% reduction) signifying progressive insulin
resistance (Figure 5C, left panel). Taken together our results
indicate a moderate increase in the level of total tau and a more
substantial increase in phospho-tau in a progressively insulin-
resistant environment.
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FIGURE 3 | Overexpression of Tau decreases pGSK-3βS9 and pERK in representative blots. Coexpression of Chico restores the levels of pGSK-3βS9 but not of
pERK. (A) Western blot analysis from flies probed with pGSK-3βS9, pERK, total GSK-3β, total ERK, and β-tubulin antibodies, respectively. (B) Western blot analysis
from flies probed with pAKT and total AKT antibodies, respectively. Quantification of phospho-antibody levels are normalized to total protein levels. (One way ANOVA
with Tukey-Kramer HSD was done for multiple group comparisons or post hoc Dunnett’s test was used for comparison with Tau, n = 3 sets of biological replicates
for each genotype.) Data represents the mean ± SEM, ∗∗P < 0.01 and ∗P < 0.05 relative to Tau in panel (A) and to Tau+Chico in panel (B). All flies were 3 days
before eclosion. Genotypes: GMR-GAL4/+; GMR-GAL4/UASChico; GMR-GAL4-gl-Tau/+; GMR-GAL4-gl-Tau/UASChico; GMR-GAL4/UASChico-RNAi;
GMR-GAL4-gl-Tau/UASChico-RNAi in panel (A). Genotypes: GMR-GAL4-gl-Tau/UASChico; GMR-gl-Tau; and GMR-gl-Tau/UASChico-RNAi in panel (B).
FIGURE 4 | Tau overexpression effects a reduction in the level TOR pathway markers but an increase in autophagy pathway markers (Atg8a-II/Atg8a-I) that are
rescued by Chico coexpression with Tau. (A,B) Western blot analysis from flies probed with P-p70S6K, P-4E-BP1, and Atg8 antibodies. β-tubulin is the loading
control. Quantification of the levels of the antibodies normalized to β-tubulin levels. (One way ANOVA with Tukey-Kramer HSD was done for multiple group
comparisons or post hoc Dunnett’s test was done for comparison with Tau, n = 3 sets of biological replicates for each genotype.) Data represents the mean ± SEM,
∗∗∗P < 0.001, ∗∗P < 0.01, and ∗P < 0.05 relative to Tau. All flies were 3 days after eclosion. Genotypes: GMR-GAL4/+; GMR-GAL4/UASChico;
GMR-GAL4-gl-Tau/+; and GMR-GAL4-gl-Tau/UASChico.
To determine whether alterations in tau phospho-epitopes
correlate with changes in the key kinases downstream of the
IR pathway, we next examined the levels of GSK-3β and ERK
using phospho-specific antibodies over a period of 4 h. We
observed a progressive decrease in phospho-GSK-3βS9/Total
GSK-3β levels to 80% compared to controls at the end of
4 h. This correlated with the gradual increase in the AT8
immunoreactivity that we observed earlier. On the contrary,
the phospho-ERK/Total ERK immunoreactivity did not change
significantly at the end of 4 h. In addition, we did not detect
any change in the level of total GSK-3β or ERK, indicating
that the change in the pattern of phosphorylated kinases is an
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FIGURE 5 | Progressive insulin treatment increases total and phosphorylated tau in SY5Y cells in an insulin resistant state. This is accompanied by the gradual
decrease in the levels of pAKT and pGSK-3βS9. SY5Y cells were serum-starved for 24 h and then treated with 100 nm insulin for various time points (0, 10, 30, 60,
120, and 240 min). After treatment, cells were harvested, lysed and immunoblotted with either (A) anti-tau (T46) and AT8 antibodies (B) IRS1-pS636 and total IRS1
or (C) pAKT, pGSK-3β, pERK, and total kinase antibodies in the representative blots. GAPDH was used as a loading control. Densitometric analyses of
phosphorylated tau (AT8) over total tau (T46) and phosphorylated kinases (pAKT, pGSK-3β, and pERK) over total kinases normalized to GAPDH were performed
based on four independent experiments. Data represent the mean ± SEM, ∗∗∗P < 0.001, ∗∗P < 0.01, and ∗P < 0.05 versus control (0 min), n = 4 biological
replicates. (One way ANOVA followed by Fisher’s test for multiple comparisons and Student’s t test for pairwise comparisons.) IR, insulin resistance.
insulin signaling pathway-specific response (Figure 5C, middle
and right panels).
In summary, our data indicates that tau hyperphosphorylation
maybe contributed by active GSK-3β but not by active ERK in
insulin-treated cells.
Insulin Treatment of SY5Y Cells
Progressively Affects the Levels of
Protein Synthesis Regulators in the
mTOR Pathway
It has been previously reported that in the normal physiological
environment and in the presence of sufficient nutrients, insulin
or insulin-like growth factors activate PI3K/AKT/mTOR
pathways subsequently promoting protein synthesis and
inhibiting autophagy (Hands et al., 2009; O’Neill, 2013). We
observed that insulin treatment of SY5Y cells initially increased
the levels of phospho-mTOR (Ser2448), phospho-p70S6K and
phospho-4E-BP1 for a period of 1 h followed by a progressive
decrease in the levels of protein biosynthesis markers as the
cells gradually entered an insulin-resistant phase at the end of
the 4-h time-period. Conversely, the ratio of autophagic marker
LC3II/LC3I increased rapidly within the first 30 min of insulin
treatment, indicating an activation of autophagy. However, at the
end of 4 h of insulin treatment, the LC3II/LC3I ratio significantly
reduced compared to earlier time points (10 and 30 min),
suggesting a blockage in the autophagic pathway (Figure 6
and Supplementary Figure S4B). These results indicate that
progressive insulin stimulation not only alters the levels of tau
and key kinases but also mediates changes in protein synthesis
and key autophagic markers in our model.
Insulin Pre-treatment of SY5Y Cells
Increases the Tau Levels by Autophagic
Impairment
To further investigate whether tau accumulation in insulin-
treated SY5Y cells was linked to an impairment of autophagy,
we pre-treated these cells with 100 nm insulin for a period of
48 h after serum starvation and exposed them to 20 nm insulin
Frontiers in Neuroscience | www.frontiersin.org 9 August 2019 | Volume 13 | Article 801
fnins-13-00801 August 1, 2019 Time: 18:37 # 10
Chatterjee et al. Insulin Resistance and Tauopathy
FIGURE 6 | Insulin treatment of SY5Y cells affects the levels of autophagic markers via mTOR pathway demonstrated by a time dependent decrease in the levels of
p-p70 S6K and p-4E-BP1 proteins. A simultaneous increase in the level of LC3-II/LC3-I ratio is observed till 30 min after which there is a decrease of autophagy in
the insulin-resistant phase. (A) SY5Y cells were treated with 100 nm insulin for different time points (0, 10, 30, 60, 120, 240 min) and lysates were analyzed by
immunoblotting with antibodies against P-p70S6K, P-4E-BP1, and LC3. GAPDH was used as a loading control. (B) Densitometric analysis of these antibodies
relative to GAPDH was performed based on four independent experiments. Data represent the mean ± SEM, ∗∗P < 0.01, ∗P < 0.05 versus control (0 min), n = 4
biological replicates (One way ANOVA followed by Fisher’s test for multiple comparisons and Student’s t test for pairwise comparisons.) IR, insulin resistance.
progressively for a period of 4 h (Son et al., 2012). In parallel,
these SY5Y cells were also exposed to bafilomycin treatment.
Bafilomycin is one of the well-known compounds that inhibit
late-stage autophagy and prevents maturation of autophagic
vacuoles by impairing the fusion between autophagosomes and
lysosomes (Mauvezin and Neufeld, 2015). Interestingly, we
observed that pre-treatment of the SY5Y cells with insulin
and bafilomycin enhanced tau staining (A0024) compared to
untreated controls (Figures 7B,C vs. Figure 7A).
Previous studies have also shown that the lack of autophagy
or blockage of autophagic flux leads to the accumulation
of p62 protein in cells (Rusten and Stenmark, 2010).
Immunohistochemical studies in SY5Y cells also showed
an increased accumulation of p62 (red) in the bafilomycin-
treated cells implying an impairment of autophagy. A similar
p62 enhancement was observed in the insulin-treated cells
confirming an inhibition of autophagy or a blockage of
autophagic flux (Figures 8B,C vs. Figure 8A).
Taken together our results show that pre-treatment of SY5Y
cells with insulin results in an inhibition of autophagy and
increased tau protein accumulation. It is worthwhile to note
that SY5Y cells treated with both insulin and bafilomycin
were toxic resulting in massive cell death possibly due to a
combination of tau aggregation and autophagic impairment
triggering apoptotic pathways.
DISCUSSION
Alzheimer’s disease is the most common cause of dementia
in humans (Citron, 2004). While plaques and tangles are
designated as pathological signatures of AD, it is now
speculated that these factors are consequential rather than
causal of the neurodegenerative cascade (Ishiguro et al., 1992;
Armstrong, 2006). Despite intense investigation, the etiology
and pathogenesis of sporadic AD remain unknown. Brain
glucose metabolism is impaired in AD, and growing evidence
supports the concept that AD is fundamentally a metabolic
disease with progressive dysfunction in brain glucose utilization
and responsiveness to insulin and insulin-like growth factor
Frontiers in Neuroscience | www.frontiersin.org 10 August 2019 | Volume 13 | Article 801
fnins-13-00801 August 1, 2019 Time: 18:37 # 11
Chatterjee et al. Insulin Resistance and Tauopathy
FIGURE 7 | Pre-treatment with insulin increases the tau protein levels in SY5Y
cells relative to untreated controls. (A–C) SY5Y cells were serum-starved for
24 h and then treated with 100 nm insulin for 48 h followed by progressive
treatment with 20 nm insulin at various time points (0, 1, 5, 10, 30, 60, 120,
and 240 min) In parallel, SHSY5Y cells were subjected to autophagy-blocker
Bafilomycin treatment for 4 h. This was followed by immunostaining by total
Tau antibody (green) and DAPI (blue). Tau immunoreactivity increased in the
insulin and bafilomycin-treated cells compared to untreated controls
(bar = 20 µm). White arrowheads represent total Tau in insulin-treated cells.
stimulation (Freude et al., 2009; Schuh et al., 2011). Although,
there have been numerous studies on peripheral insulin
resistance, the mechanism of central insulin resistance and
particularly its impact on tau, one of the hallmarks of AD, is
relatively unknown.
Our laboratory has generated a model of tauopathy in
Drosophila by expressing human wild-type full-length tau
(2N/4R) in the retina, that results in a “rough-eye” phenotype
(Jackson et al., 2002; Chatterjee et al., 2009). This tau-induced
eye phenotype is highly useful for conducting unbiased
enhancer/suppressor screens through which Chico-the single
fly homolog of mammalian IRS was identified as a suppressor
of tau-induced “rough-eye” phenotype (Ambegaokar and
Jackson, 2011). Recent studies show that loss-of-function
mutation in Chico causes insulin resistance by increasing
the amount of circulating trehalose and lipids in Drosophila
(Murillo-Maldonado et al., 2011; Naganos et al., 2012).
Our data demonstrates that Chico ameliorates the tau-
induced neurotoxicity by reducing tau aggregation and
hyperphosphorylation at the disease epitopes while Chico-LOF
exacerbates these effects. The exacerbation of tau pathology by
Chico-LOF was attributed to insulin resistance as these flies
displayed 50% reduction in Drosophila AKT phosphorylated
at Serine505 residue that corresponds with insulin resistance
in mammalian AKT phosphorylated at Serine473 residue
(Standaert et al., 2002). Our results further show that this
augmentation is achieved by modulating the kinase GSK-
3β, which lies downstream of the IR signaling pathway.
Finally, we demonstrate that Chico impacts mTOR/autophagy
pathway, thus playing a significant role in clearance of tau
aggregates. These observations in the Drosophila tauopathy
model were further validated in mammalian neuroblastoma
FIGURE 8 | Pre-treatment with insulin increases the p62 protein levels in
SY5Y cells relative to untreated controls. (A–C) SY5Y cells were
serum-starved for 24 h and then pre-treated with 100 nm insulin for 48 h,
followed by immunostaining with p62 (red) antibody. In parallel, SHSY5Y cells
were subjected to autophagy-blocker bafilomycin treatment for 4 h. The
intensity of p62 was greater in insulin and bafilomycin-treated cells (B,C)
compared to untreated cells (A) as observed by fluorescence microscopy
implying an autophagic blockage. DAPI (blue) was used as a nuclear stain
(bar = 20 µm). White arrowheads represent p62 in insulin-treated cells.
cells, implying a conservation of these pathways across
diverse systems.
In post-mortem brains from AD patients, tau phosphorylation
was found to increase at several GSK-3β directed epitopes
such as AT8, AT180, AT100, and PHF1 (Ishiguro et al., 1992;
Armstrong, 2006). GSK-3β is one of the key tau kinases
that also colocalizes with tau tangles and microtubules in
the brains from patients with AD (Hooper et al., 2008;
Avila et al., 2012). Interestingly, GSK-3β is regulated by the
insulin signaling pathway. Briefly, insulin signaling is initiated
by the binding of insulin to its receptor, located in the
cytoplasmic membrane. This leads to rapid phosphorylation
of IRSs that activate PI3K/AKT signaling in the brain (Diehl
et al., 2017). AKT phosphorylates GSK-3β at Serine 9, thereby
inhibiting its activity of tau hyperphosphorylation and facilitating
binding to microtubules. Conversely, when GSK-3β is in an
active state (due to phosphorylation at Tyrosine 216 residue),
it phosphorylates tau to generate AT8 and PHF1 disease
epitopes (Chatterjee et al., 2009). In another independent
study Barone et al. have shown that reduction of Biliverdin
reductase-A (BVR-A) in the hippocampus of 3xTg-AD mice
impairs AKT-mediated inhibition of GSK-3β and increases tau
phosphorylation in response to oxidative stress. They have
also shown that increased GSK-3β activation (decreased Serine
9 phosphorylation) is detected in the early stages of AD
(Sharma et al., 2019).
In our study we observe, that co-expression of Chico
with Tau significantly increases the level of inactive GSK-
3β phosphorylated at Serine9 residue and reduces tau
hyperphosphorylation. Conversely, the coexpression of insulin-
resistant Chico-LOF activates GSK-3β and exacerbates tau
hyperphosphorylation. Our results are supported by the studies
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of Jolivalt et al. (2008) and Kim et al. (2009) in which STZ-
induced type-1 diabetic mouse models display an increased tau
hyperphosphorylation mediated by active GSK-3β (Doble and
Woodgett, 2003; Kim et al., 2009). Interestingly this effect was
not observed in type 2 diabetic mouse models. Our study differs
significantly in this respect since the genetically manipulated
Chico-LOF mutants recapitulate features of type 2 diabetes and
not of type 1 diabetes.
To examine whether insulin-resistance – induced tau
enhancement was conserved in the mammalian system, these
experiments were repeated in insulin treated SY5Y cells. It
has been observed in human hippocampal tissue that insulin
resistance is accompanied by an increased phosphorylation at the
Serine636 residues of IRS-1 (Copps and White, 2012; Diehl et al.,
2017). Interestingly we observed a progressive increase in the
ratio of phospho-IRS1/Total IRS1 from 30 min to 4 h time period
signifying insulin resistance. This was also confirmed by an 80%
reduction of phospho-AKT/Total AKT at the 4 h time-period
confirming insulin resistance in SY5Y cells.
Interestingly, while we observed an initial decrease in total
and AT8-tau levels, there was a sharp increase in the AT8/T46
ratios as the cells entered an insulin resistant condition. Our
studies are in contrast to the studies done by Lesort et al.
(1999) who treated the SY5Y cells with 10 nm insulin and
observed a transient increase in AT8-tau hyperphosphorylation
at the early time points (0–60 min) and dephosphorylation
post 1 h. In comparison, we have used 100 nm insulin
which generated insulin resistance after 30 min of treatment
subsequently increasing levels of total and phospho-tau. In this
respect, the early time points in SY5Y cells recapitulate our
observations from Chico gain-of-function while the later time
points pertaining to insulin-resistance represent Chico loss-of-
function or knock-down flies.
Several studies have shown that hyperphosphorylated tau
dislodges from the microtubules and binds with tau monomers
to form tau aggregates. These abnormal tau aggregates are
considered to be a critical pathological feature of tauopathy
(Cowan et al., 2015; Goedert and Spillantini, 2017). It is
hypothesized that small molecular weight, sarcosyl-soluble tau
aggregates gradually consolidate to form NFTs that are sarcosyl-
insoluble. However, the toxicity of the sarcosyl soluble and
insoluble aggregates remains controversial. A study by Lasagna-
Reeves et al. (2011) showed that the injection of soluble
tau oligomers but not monomers or fibrils were sufficient in
inducing synaptic dysfunctions and cognitive impairments in
wild type mouse. There are others studies that show the spread
of soluble tau across the synapses for the propagation of tau
pathology while the insoluble tau fibrils within the neurons
act as a “sink” to sequester the toxic and soluble tau species
(Kopeikina et al., 2012). Although, Chico-LOF exacerbates
the tau-induced toxicity in the “rough-eye” phenotype, we
detect a significant amount of insoluble tau species in these
transgenics. Taking into account the prevailing literature in
this area, there is a possibility that the shift of tau from
soluble to insoluble aggregates in an insulin-resistant state is
a defense mechanism of neurons in response to progressive
tau accumulation.
Aggregates of tau are removed by macroautophagy (Inoue
et al., 2012; Neufeld, 2012). The protein kinase TOR, an
evolutionarily conserved protein, plays a central role in regulating
macroautophagy in response to nutrient availability and stress
factors (Miron et al., 2003). The involvement of TOR pathway
in Drosophila neurodegeneration models have been controversial
depending on disease model in question. Feany and colleagues
and Berger et al. (2006) have previously reported that TOR
pathways components enhance mutant tau (R406W) induced
toxicity in their fly models that is ameliorated by treatment
with TOR inhibitor rapamycin (Khurana et al., 2006; Khurana
et al., 2010). These observations have also been supported by
Caccamo et al. (2013) in P301S mouse models where increasing
mTOR activity has been shown to increase tau pathology
whereas decreasing mTOR ameliorates tau-induced neuronal
dysfunctions and pathology. In contrast, we observe a down-
regulation of the TOR pathway in our tauopathy models that
is rescued by coexpression of Chico. One possibility is that we
have used wild type full-length human tau in our fly models as
opposed to mutant tau used in the studies above. An interesting
study by Tramutola et al. (2015) in post-mortem AD brains
reports significant upregulation of PI3K/AKT/mTOR pathways
in both MCI and late stage AD but not in the early stage AD.
Since we have used 0–3 days old adult flies for this study, it is
possible that our tauopathy model represents an early stage of
pathology during which the PI3K/AKT/mTOR signaling pathway
is not yet activated.
In keeping with decreased TOR function, we observe a
simultaneous upregulation of autophagy in Tau transgenics. This
was measured by elevated levels of membrane bound Atg8a-
II relative to unbound Atg8a-I. We also observe a similar
upregulation of autophagy in Tau+Chico-LOF transgenics.
However, an upregulation of autophagy does not necessarily
mean autophagic clearance. A recent study by Bakhoum et al.
(2014) demonstrates the formation of giant autophagic bodies
(GABS) in retinas of tauopathy models that arise due to
incomplete acidification of autophagolysosomes and culminates
in an impairment of autophagic flux. Although we did not see
an autophagic blockage in our freshly eclosed progeny, further
experiments need to be done with aged Tau flies. The relationship
between insulin resistance and autophagy is a relatively new field
with contradicting observations depending on animal or cellular
model in question. Recent studies in cellular models of carcinoma
show that insulin resistance activates autophagy (Zhou et al.,
2009). In contrast, studies done in APP/PS1 mice show that
insulin sensitivity improves autophagy in neurodegenerative
disease models (Macklin et al., 2017). Thus, in our Tauopathy
model, the impact of hyperphosphorylated and aggregated tau on
autophagic clearance in an insulin-resistant environment cannot
be ruled out (Rodriguez-Rodriguez et al., 2017).
In SY5Y cells, prolonged treatment with insulin resulted
in downregulation of the mTOR pathway in an insulin-
resistant environment. Interestingly, our data matches
with the observations of Barone et al. (2016) who report
mTOR activation at lower concentrations of insulin but a
subsequent decrease in higher insulin concentrations in SY5Y
cells. However, instead of an upregulation of autophagy,
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FIGURE 9 | Schematic of a proposed model of tau hyperphosphorylation under the conditions of normal and impaired insulin signaling. (A) Insulin signaling in a
physiological environment activates AKT, which in turn inactivates GSK-3β and prevents tau hyperphosphorylation. Insulin also activates TOR pathway for cellular
growth and maintains a basal level of autophagy for cell survival. (B) An impaired insulin signaling results in an inactivation of AKT and an activation of GSK-3βY216
resulting in tau hyperphosphorylation leading to the formation of insoluble tau aggregates. The pathological condition is exacerbated by an impaired clearance of
toxic protein.
we observed an autophagic blockage that was evident by
decreased LC3-II signaling in insulin-treated cells compared
to controls. These results were further validated by the
accumulation of p62 protein in insulin-treated cells indicating
an autophagic blockage akin to the treatment of the cells
with known autophagy blocker Bafilomycin (Bartlett et al.,
2011; Cai et al., 2012). It is possible that the autophagic
upregulation observed at the early time points was atleast partly
contributed by the serum starvation before subjecting the cells to
insulin treatment.
Taken together our results imply that insulin resistance
increases the amount hyperphosphorylated tau not only
by activating the key kinases but also by modulating the
TOR/autophagy pathways.
Therefore, we propose a speculative mechanism of insulin
sensitivity and resistance in our fly and cellular models. In an
insulin-sensitive state there exists an optimal physiological
level of total and phospho-tau partially controlled by
the principal tau kinase GSK-3β located downstream of
the insulin signaling pathway. This situation is reversed
in an insulin-resistant state with dysregulation of the
downstream kinases that result in the increased production
of hyperphosphorylated and aggregated tau. Despite increased
autophagic induction, abnormal tau accumulation is aggravated
by impaired autophagic clearance ultimately causing neuronal
death (Figure 9).
This study, for the first time highlights the role of Chico –
the ortholog of mammalian IRSs in playing a crucial role in
reducing tau hyperphosphorylation and aggregation in our
tauopathy models by controlling the downstream tau kinases
GSK-3β and ERK and modulating the mTOR/autophagy
pathways. The recapitulation of the in vivo data in mammalian
cells stresses the fact that the insulin signaling pathway
is conserved in both systems. Our study deciphers a
compelling linkage between insulin resistance in type 2
diabetes and tau pathology observed in 4R-tauopathies
including AD. Further elucidation of the mechanisms may
pave the way for the early detection of risk factors such
as insulin resistance and designing of novel drug targets
(Huang and Mucke, 2012).
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